Key Highlights

  • Loss per share was USD 0.15 against an estimate of a USD 0.13 loss.
  • Net loss was USD 27.17 million, against USD 14.26 million a year earlier.
  • Research and development expense was USD 22.04 million, against USD 12.83 million.
  • Cash and marketable securities were USD 163 million at September 30.

Compass Therapeutics (NASDAQ:CMPX) reported a third quarter 2026 loss per share of USD 0.15, against an estimate of a USD 0.13 loss and a USD 0.08 loss in the third quarter of 2025. Net loss was USD 27.17 million, compared with USD 14.26 million in the prior-year quarter.

The loss from operations was USD 28.80 million, against USD 15.82 million a year earlier. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

Operating Expenses and Interest Income

Research and development expense was USD 22.04 million, compared with USD 12.83 million. General and administrative expense was USD 6.76 million, compared with USD 2.99 million. Total operating expenses were USD 28.80 million, against USD 15.82 million.

Interest income was USD 1.63 million, compared with USD 1.56 million. For the nine months, total operating expenses were USD 76.08 million, against USD 54.85 million, and interest income was USD 5.44 million, against USD 4.08 million.

Nine-Month Results

Net loss for the nine months ended September 30, 2026 was USD 70.64 million, compared with USD 50.77 million in the same period of 2025, and the nine-month loss per share was USD 0.38, against USD 0.34. Research and Development expense for the nine months was USD 55.00 million, against USD 42.30 million, and general and administrative expense was USD 21.08 million, against USD 12.55 million.

Stock-based compensation within general and administrative expense was USD 2.15 million for the quarter, compared with USD 0.39 million, and total stock-based compensation was USD 4.01 million, against USD 1.24 million. The filing cautions that there is no assurance research and development can be successfully completed, that adequate protection for the technology can be obtained, that products can obtain regulatory approval or that approved products can be commercially viable.

Funding and Collaboration Agreements

As of September 30, 2026, the company had USD 163 million in cash, cash equivalents and marketable securities, including cash and cash equivalents of USD 41.47 million and marketable securities of USD 121.59 million.

The filing states that through September 30, 2026, the company has received USD 568 million in gross proceeds from the sale of Equity securities, including an offering with aggregate net proceeds of USD 129.3 million after Underwriting discounts and commissions of USD 8.3 million and other offering costs of USD 0.4 million. It also describes a license agreement from November 2018 with ABL Bio, a South Korean biotechnology company, granting an exclusive global license, excluding South Korea, to tovecimig (ABL001).

Compass Therapeutics Q3 2026 Earnings: Key Takeaways

Compass Therapeutics reported a third quarter 2026 loss per share of USD 0.15 and a net loss of USD 27.17 million. Research and development expense was USD 22.04 million, and cash, cash equivalents and marketable securities were USD 163 million.